ATRS
Income statement / Annual
Last year (2021), Antares Pharma, Inc.'s total revenue was $183.98 M,
an increase of 22.98% from the previous year.
In 2021, Antares Pharma, Inc.'s net income was $46.29 M.
See Antares Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
Operating Revenue |
$183.98 M |
$149.60 M |
$123.86 M |
$63.55 M |
$54.52 M |
$52.22 M |
$45.66 M |
$26.50 M |
$20.62 M |
$22.58 M |
Cost of Revenue |
$68.28 M
|
$63.10 M
|
$50.48 M
|
$31.07 M
|
$27.47 M
|
$28.82 M
|
$19.46 M
|
$11.24 M
|
$9.20 M
|
$9.52 M
|
Gross Profit |
$115.70 M
|
$86.50 M
|
$73.39 M
|
$32.49 M
|
$27.05 M
|
$23.41 M
|
$26.20 M
|
$15.26 M
|
$11.42 M
|
$13.06 M
|
Gross Profit Ratio |
0.63
|
0.58
|
0.59
|
0.51
|
0.5
|
0.45
|
0.57
|
0.58
|
0.55
|
0.58
|
Research and Development Expenses |
$14.50 M
|
$10.12 M
|
$10.62 M
|
$12.33 M
|
$13.15 M
|
$21.13 M
|
$19.73 M
|
$18.64 M
|
$15.26 M
|
$14.92 M
|
General & Administrative Expenses |
$0.00
|
$62.76 M
|
$61.77 M
|
$36.76 M
|
$30.35 M
|
$26.39 M
|
$26.93 M
|
$31.74 M
|
$8.29 M
|
$7.20 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.71 M
|
$2.38 M
|
Selling, General & Administrative Expenses |
$73.86 M
|
$62.76 M
|
$61.77 M
|
$36.76 M
|
$30.35 M
|
$26.39 M
|
$26.93 M
|
$31.74 M
|
$17.01 M
|
$9.59 M
|
Other Expenses |
$68.28 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$156.64 M
|
$72.88 M
|
$72.40 M
|
$49.09 M
|
$43.50 M
|
$47.52 M
|
$46.66 M
|
$50.38 M
|
$32.27 M
|
$24.51 M
|
Cost And Expenses |
$224.92 M
|
$135.98 M
|
$122.87 M
|
$80.16 M
|
$70.97 M
|
$76.34 M
|
$66.12 M
|
$61.61 M
|
$41.47 M
|
$34.03 M
|
Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$79,783.00
|
$60,469.00
|
$76,661.00
|
$111,577.00
|
$63,195.00
|
Interest Expense |
$0.00
|
$3.79 M
|
$3.55 M
|
$2.68 M
|
$1.42 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$3.90 M
|
$2.63 M
|
$2.56 M
|
$2.72 M
|
$2.10 M
|
$1.86 M
|
$1.57 M
|
$1.22 M
|
$558,280.00
|
$231,028.00
|
EBITDA |
$66.17 M |
$16.34 M |
$4.08 M |
-$1.12 M |
-$13.22 M |
-$22.38 M |
-$18.91 M |
-$33.90 M |
-$20.25 M |
-$11.20 M |
EBITDA Ratio |
0.36
|
0.11
|
0.03
|
-0.02
|
-0.24
|
-0.43
|
-0.41
|
-1.28
|
-0.98
|
-0.5
|
Operating Income Ratio |
0.34
|
0.09
|
0.01
|
-0.06
|
-0.3
|
-0.46
|
-0.45
|
-1.32
|
-1.01
|
-0.51
|
Total Other Income/Expenses Net |
$0.00
|
-$3.70 M
|
-$3.02 M
|
-$2.41 M
|
-$292,000.00
|
-$122,344.00
|
-$21,867.00
|
-$13,420.00
|
$43,541.00
|
$24,049.00
|
Income Before Tax |
$62.27 M
|
$9.92 M
|
-$2.03 M
|
-$6.52 M
|
-$16.74 M
|
-$24.24 M
|
-$20.48 M
|
-$35.13 M
|
-$20.81 M
|
-$11.43 M
|
Income Before Tax Ratio |
0.34
|
0.07
|
-0.02
|
-0.1
|
-0.31
|
-0.46
|
-0.45
|
-1.33
|
-1.01
|
-0.51
|
Income Tax Expense |
$15.98 M
|
-$46.28 M
|
$530,000.00
|
$261,000.00
|
$1.13 M
|
$100,000.00
|
$175,000.00
|
$25,000.00
|
-$300,000.00
|
$24,049.00
|
Net Income |
$46.29 M
|
$56.20 M
|
-$2.03 M
|
-$6.52 M
|
-$16.74 M
|
-$24.34 M
|
-$20.66 M
|
-$35.15 M
|
-$20.51 M
|
-$11.43 M
|
Net Income Ratio |
0.25
|
0.38
|
-0.02
|
-0.1
|
-0.31
|
-0.47
|
-0.45
|
-1.33
|
-0.99
|
-0.51
|
EPS |
0.27 |
0.33 |
-0.01 |
-0.04 |
-0.11 |
-0.16 |
-0.14 |
-0.27 |
-0.16 |
-0.1 |
EPS Diluted |
0.27 |
0.33 |
-0.01 |
-0.04 |
-0.11 |
-0.16 |
-0.14 |
-0.27 |
-0.16 |
-0.1 |
Weighted Average Shares Out |
$170.16 M
|
$170.16 M
|
$202.70 M
|
$162.88 M
|
$156.05 M
|
$154.99 M
|
$146.59 M
|
$130.55 M
|
$126.90 M
|
$110.19 M
|
Weighted Average Shares Out Diluted |
$170.16 M
|
$170.16 M
|
$202.70 M
|
$162.88 M
|
$156.05 M
|
$154.99 M
|
$146.59 M
|
$130.55 M
|
$126.90 M
|
$110.19 M
|
Link |
|
|
|
|
|
|
|
|
|
|